Publications by authors named "Mark Boldrin"

Claim this Profile
D
Dose-Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short-Term Multiple Doses in Patients With Type 2 Diabetes Mellitus.
Jianguo Zhi, Suoping Zhai, Mark Boldrin

Clin Pharmacol Drug Dev· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus.
Angela Georgy, Suoping Zhai, Zhenming Liang, Mark Boldrin, Jianguo Zhi

J Clin Pharmacol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.
Jianguo Zhi, Suoping Zhai, Angela Georgy, Zhenming Liang, Mark Boldrin

J Clin Pharmacol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.
Julio Rosenstock, Bogdan Balas, Bernard Charbonnel, Geremia B Bolli, Mark Boldrin

Diabetes Care· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial).
Richard M Bergenstal, Adriana Forti, Jean-Louis Chiasson, Michael Woloschak, Mark Boldrin

Diabetes Ther· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).
Itamar Raz, Vivian Fonseca, Mark Kipnes, Laurence Durrwell, John Hoekstra, Mark Boldrin

Diabetes Care· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.
Michael A Nauck, Robert E Ratner, Christoph Kapitza, Rachele Berria, Mark Boldrin

Diabetes Care· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
James W Anderson, Susan M Schwartz, Jonathan Hauptman, Mark Boldrin, Maureen Rossi

Ann Pharmacother· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
Jean-Pierre Chanoine, Sarah Hampl, Craig Jensen, Mark Boldrin, Jonathan Hauptman

JAMA· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
Jarl S Torgerson, Jonathan Hauptman, Mark N Boldrin, Lars Sjöström

Diabetes Care· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia.
Charles P Lucas, Mark N Boldrin, Gerald M Reaven

Am J Cardiol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis